BioSpace News Archive

VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE® (pancrelipase) Delayed Release Capsules that extends the shelf life to 36 months across all PANCREAZE dosages.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it intends to discuss with the FDA and EMA (European Medicines Agency) plans to conduct a single arm Phase 2 trial that would serve as the basis for accelerated approval of Liposomal Annamycin (“Annamycin”) to treat relapsed or refractory acute myeloid leukemia (“AML”).

Sutro Biopharma, Inc. (NASDAQ: STRO), today announced the expansion of its senior management team with the appointments of Kristin Bedard, Ph.D., as Vice President of Immunobiology, and Brunilda Shtylla as Vice President of Business Development.

Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy® System in the treatment of advanced rectal cancer.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 19, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Conformis, Inc., a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy, announced that the Company has appointed Bob Howe as its new Chief Financial Officer, and Gary Maingot as SVP, Operations.

Ichnos Sciences Inc. is pleased to announce that Gabriela Gruia, M.D. has assumed the role of Chief Development Officer, effective immediately.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold a conference call for investors on Wednesday, February 19, 2020, at 5:00 p.m. Eastern Time.

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the first published case report detailing the successful use of CytoSorb to help treat cytokine release syndrome (CRS) following the administration of CAR T-cell immunotherapy

Advanced Medical Pricing Solutions (AMPS), the pioneer in cost containment for the self-insurance industry, today announced the appointment of Attorney Laura A. Conte, a healthcare legal industry veteran with a quarter-century of experience, as General Counsel.